Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

1.

Antidepressants and their effect on cognition in major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2015 Aug;76(8):e1046.

PMID:
26335095
2.

Reply to commentary by Rothschild: "A Blood Test for Depression?"

Papakostas GI, Shelton RC, Henry ME, Bilello JA.

J Clin Psychiatry. 2015 Aug;76(8):e1038. No abstract available.

PMID:
26335092
3.

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.

Papakostas GI, Ionescu DF.

Mol Psychiatry. 2015 Jul 7. doi: 10.1038/mp.2015.92. [Epub ahead of print]

PMID:
26148812
4.

Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.

Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ.

J Affect Disord. 2015 Oct 1;185:24-30. doi: 10.1016/j.jad.2015.06.038. Epub 2015 Jun 25.

PMID:
26142691
5.

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.

Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC.

Am J Psychiatry. 2015 Jun 18:appiajp201514101251. [Epub ahead of print]

PMID:
26085041
6.

Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial.

Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D.

Pharmacopsychiatry. 2015 Jul;48(4-05):141-4. doi: 10.1055/s-0035-1549928. Epub 2015 May 26.

PMID:
26011569
7.

Understanding and managing Cognition in the Depressed Patient.

Papakostas GI, Culpepper L.

J Clin Psychiatry. 2015 Apr;76(4):418-25. doi: 10.4088/JCP.13086ah1c. Review.

PMID:
25919832
8.

MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.

Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI.

J Clin Psychiatry. 2015 Feb;76(2):e199-206. doi: 10.4088/JCP.14m09029.

9.

The nature of placebo response in clinical studies of major depressive disorder.

Papakostas GI, Østergaard SD, Iovieno N.

J Clin Psychiatry. 2015 Apr;76(4):456-66. doi: 10.4088/JCP.14r09297.

PMID:
25700292
10.

Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.

Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI.

J Psychiatr Res. 2015 Mar;62:56-61. doi: 10.1016/j.jpsychires.2015.01.007. Epub 2015 Jan 26.

PMID:
25659187
11.

Updates and trends in the treatment of major depressive disorder.

Papakostas GI, Ionescu DF.

J Clin Psychiatry. 2014 Dec;75(12):1419-21. doi: 10.4088/JCP.14ac09610.

PMID:
25551237
12.

An overview of vortioxetine.

Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME.

J Clin Psychiatry. 2014 Dec;75(12):1411-8. doi: 10.4088/JCP.14027ah1. Review.

13.

Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group.

Chen JA, Vijapura S, Papakostas GI, Parkin SR, Kim DJ, Cusin C, Baer L, Clain AJ, Fava M, Mischoulon D.

Asian J Psychiatr. 2015 Feb;13:23-9. doi: 10.1016/j.ajp.2014.12.002. Epub 2014 Dec 9.

14.

Dr. Mischoulon and colleagues reply.

Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M.

J Clin Psychiatry. 2014 Nov;75(11):e1328-9. doi: 10.4088/JCP.14lr09266a. No abstract available.

PMID:
25470103
15.

Predictors of placebo response in bipolar depression.

Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI.

Int Clin Psychopharmacol. 2015 Mar;30(2):59-66. doi: 10.1097/YIC.0000000000000058.

PMID:
25438027
16.

S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.

Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D.

J Affect Disord. 2014 Aug;164:76-81. doi: 10.1016/j.jad.2014.03.041. Epub 2014 Apr 1.

PMID:
24856557
17.

Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.

Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, DiPierro M, Cardoos A, Papakostas GI.

Int Clin Psychopharmacol. 2014 Nov;29(6):332-8. doi: 10.1097/YIC.0000000000000039.

PMID:
24815673
18.

Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.

Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl SM, Fava M.

J Clin Psychiatry. 2014 Aug;75(8):855-63. doi: 10.4088/JCP.13m08947.

PMID:
24813065
19.

A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.

Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K, Walker R, Ludington E, Fava M.

J Clin Psychiatry. 2014 Apr;75(4):370-6. doi: 10.4088/JCP.13m08591.

PMID:
24500245
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk